Streetbeat News

BMEA

Biomea Fusion, Inc.

Industry

Biotechnology

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Open

2.73

Mkt cap

92M

Volume

650K

High

2.80

P/E Ratio

-0.63

52-wk high

17.89

Low

2.48

Div yield

N/A

52-wk low

2.35

The article lists the stocks that gained and lost the most in Monday's mid-day session. Tupperware Brands Corporation (TUP), Vinco Ventures (BBIG), and Spark Networks (LOV) were among the top gainers, while AppHarvest (APPH), Kodiak Sciences (KOD), and BioCardia (BCDA) were among the top losers. Ryanair Holdings (RYAAY) shares fell by 8.3% after the company reported quarterly results.

Portfolio Pulse from Lisa Levin

July 24, 2023 | 6:54 pm

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Biomea Fusion (NASDAQ:BMEA) and maintained a $50 price target.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 4:51 pm

Biomea Fusion Inc (NASDAQ:BMEA) released preliminary data from its ongoing Phase 1 COVALENT-101 trial, showing initial responses in AML patients with menin-dependent mutations. The analysis showed complete responses in 2 of 5 AML patients. The company also announced the commencement of enrollment for Dose Level 5 to further optimize and explore the potential to improve upon these preliminary results. Despite this, BMEA shares are down 9.71% at $19.44.

Portfolio Pulse from Vandana Singh

July 24, 2023 | 4:09 pm

Biomea Fusion, Inc. (NASDAQ:BMEA) has announced preliminary topline data from its ongoing Phase I clinical trial, COVALENT-101, for its investigational drug BMF-219. The drug, designed to treat patients with genetically defined cancers and metabolic diseases, showed 2 complete responses out of 5 relapsed/refractory AML patients carrying menin-dependent mutations treated at Dose Level 4. The safety profile of BMF-219 supports further dose escalation, and enrollment for Dose Level 5 has commenced. The company plans to submit additional details of this clinical data set at an upcoming medical conference.

Portfolio Pulse from Happy Mohamed

July 24, 2023 | 1:08 pm

EF Hutton analyst Tony Butler has reiterated a 'Buy' rating on Biomea Fusion (NASDAQ:BMEA) and maintained a price target of $43.

Portfolio Pulse from Benzinga Newsdesk

July 12, 2023 | 5:33 pm

18 analysts have provided ratings for Biomea Fusion (NASDAQ:BMEA) in the last quarter, with an average price target of $45.72, implying an upside from the current price of $24.415. The majority of ratings are bullish, and the average price target has increased by 14.04% over the past month.

Portfolio Pulse from Benzinga Insights

June 26, 2023 | 9:01 pm

U.S. stocks traded mixed with the Dow Jones gaining over 50 points, while NASDAQ and S&P 500 fell. Energy shares jumped by 2.2% and communication services shares dipped by 1.4%. TRxADE HEALTH, MoonLake Immunotherapeutics, and Benitec Biopharma saw significant gains, while Avalo Therapeutics, FibroGen, and Biomea Fusion experienced declines.

Portfolio Pulse from Lisa Levin

June 26, 2023 | 7:21 pm

Biomea Fusion's stock initially rose after announcing new clinical data from its ongoing Phase II study of BMF-219 in type 2 diabetes patients, but has since sold off.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 4:45 pm

Carnival Corporation shares fell 9% after reporting Q2 financial results and issuing guidance. Other stocks experienced significant gains and losses during Monday's mid-day session, with Benitec Biopharma, TRxADE HEALTH, and MoonLake Immunotherapeutics among the top gainers, while Avalo Therapeutics and FibroGen saw significant declines.

Portfolio Pulse from Lisa Levin

June 26, 2023 | 4:31 pm

Carnival Corporation (NYSE:CCL) shares dropped over 9% after reporting Q2 revenue of $4.91 billion, beating the consensus estimate of $4.77 billion, and an adjusted loss of 31 cents per share, beating estimates for a loss of 34 cents per share. Crude oil prices rose, and U.S. stocks traded lower with the Nasdaq dropping around 80 points.

Portfolio Pulse from Lisa Levin

June 26, 2023 | 4:09 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.